source
- Novartis' DM1 drug del-desiran misses primary endpoint in Phase 3 HARBOR trialNovartis announced that its experimental therapy del-desiran did not improve muscle function in a pivotal Phase 3 study for myotonic dystrophy type 1 (DM1). The trial, called HARBOR, evaluated the…
- Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drugIn the wake of its high-profile setback in heart disease late last week, Novartis really needed a win. It didn’t get one. The Swiss pharma said Tuesday that in a late-stage ...Endpoints · 1h ago↗ source